Sign In
Buy CLVLY
$6.40
-0.0800 (-1.23%)
At Close: Jun 03, 2026
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
01:47am, Friday, 24'th Apr 2026
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated diseas
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
02:18am, Wednesday, 15'th Apr 2026
MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL's innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeti
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2026 Earnings Call Transcript
08:28am, Thursday, 26'th Feb 2026
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2026 Earnings Call Transcript
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
09:37pm, Sunday, 07'th Dec 2025
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery plat
Clinuvel Pharmaceuticals Limited (CLVLY) Shareholder/Analyst Call Transcript
05:05pm, Monday, 20'th Oct 2025
Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Shareholder/Analyst Call October 16, 2025 7:00 PM EDT Company Participants Jeffrey Rosenfeld Susan Smith Matthew Pringle Malcolm Bull - Head of Australia
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
10:56pm, Sunday, 28'th Sep 2025
Next generation sustained-release formulations for a variety of peptides Next generation sustained-release formulations for a variety of peptides
Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2025 Earnings Call Transcript
09:19am, Thursday, 28'th Aug 2025
Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q4 2025 Earnings Conference Call August 28, 2025 4:00 AM ET Company Participants Malcolm Bull - Head of Australian Operations & Investor Relations Peter
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
03:43am, Friday, 22'nd Aug 2025
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL's primary listing on the ASX will remai
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
12:10am, Wednesday, 07'th May 2025
CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled
Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025
09:17pm, Monday, 03'rd Mar 2025
MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call Transcript
06:17pm, Friday, 28'th Feb 2025
Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q2 2025 Results Conference Call February 27, 2025 2:00 AM ET Company Participants Stella Mariss - Monsoon Communications Malcolm Bull - Head of IR Peter
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
07:07pm, Monday, 30'th Sep 2024
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotid
Afamelanotide in fair-skinned Parkinson's patients
08:39pm, Monday, 17'th Jun 2024
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson's Disease (PD or Parkinson's)
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
04:25am, Thursday, 28'th Mar 2024
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanoti
Malibu shines a light on CLINUVEL's pioneering work in photomedicine
09:38pm, Monday, 04'th Mar 2024
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California's most prolific investors and philanthropists at the
